ABVC_OUT_1 [2025-04-01 09:55:57 -0400] 2477 Bytes | 697 tokens | Cum: 697 tkns (8.71% of 8k)
==========================================================================

Booyah, my friends! It's already 9:55:56 AM on Tue Apr 01, 2025 -0400, and I've got my eyes locked on ABVC BioPharma (ABVC), pushing up to 1.25 from 1.06. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for ABVC BioPharma:

C1 - Mar-19-25 09:00AM - ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential
C2 - Mar-05-25 04:01PM - ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs
C3 - Feb-26-25 04:01PM - ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets
C4 - Feb-20-25 09:00AM - ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025
C5 - Feb-12-25 08:30AM - Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion
C6 - Jan-16-25 08:30AM - ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference
C7 - Jan-15-25 08:30AM - ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market
C8 - Jan-14-25 08:30AM - AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

Prior AI Reports for ABVC:
1. 2025-03-31 – Score: 1 – Target: 1.1400 – Highs: 1.0900 / – / –
impressive-quarter-performance-amid-tough-financial-indicators

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ABVC BioPharma (ABVC)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ABVC_OUT_3 [2025-04-01 09:55:58 -0400] 1099 Bytes | 284 tokens | Cum: 983 tkns (12.29% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential**
Date: Mar-19-25 09:00AM
Source: (NewMediaWire)
URL: https://finance.yahoo.com/news/abvc-biopharma-maintains-lucrative-global-130000193.html

FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) -ABVC BioPharma, Inc.(NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment receivables per global licensing agreements and $60 million CDMO acquisition, reinforcing its strategic positioning for long-term growth. With three major global licensing agreements across psychiatric disorders, ophthalmic medical devices, and oncology, coupled with a fully integrated pharmaceutical manufacturing facility, we believe that AB

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ABVC_OUT_5 [2025-04-01 09:56:00 -0400] 900 Bytes | 261 tokens | Cum: 1246 tkns (15.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T17:05:39Z - 12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), bluebird b...
A2 - 2025-03-19T13:04:45Z - EQS-News: ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquis...
A3 - 2025-03-07T12:23:07Z - ABVC BioPharma to invest $220m into US pharmaceutical manufacturing, raw material cultivation...
A4 - 2025-03-05T14:01:03Z - EQS-News: ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products f...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ABVC_OUT_7 [2025-04-01 09:56:07 -0400] 1098 Bytes | 340 tokens | Cum: 1588 tkns (19.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), bluebird bio (NASDAQ:BLUE)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44567209/12-health-care-stocks-moving-in-mondays-intraday-sessionGainers Corcept Therapeutics CORT stock moved upwards by 88.8% to $103.12 during Monday's regular session. The market value of their outstanding shares is at $10.8 billion. Regencell Bioscience RGC stock increased by 38.2% to $35.48. The company's market cap stands at $461.6 million. Citius Oncology CTOR shares rose 34.34% to $0.89. The market value of their outstanding shares is at $63.9 million. bluebird bio BLUE shares rose 26.41% to $5.16. The market value of their outstanding shares is at $50.2 million. The company's, Q4 earnings came out 2 days ago. WORK Medi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ABVC_OUT_9 [2025-04-01 09:56:07 -0400] 1070 Bytes | 344 tokens | Cum: 2113 tkns (26.41% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-04-18T13:25:00Z - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
B2 - 2024-03-26T12:30:00Z - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
B3 - 2024-03-14T13:30:00Z - ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
B4 - 2024-02-08T14:17:00Z - ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
B5 - 2024-01-04T18:37:44Z - Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B6 - 2024-01-04T12:59:32Z - Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ABVC_OUT_11 [2025-04-01 09:56:12 -0400] 1051 Bytes | 288 tokens | Cum: 2403 tkns (30.04% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/03/14/2846367/0/en/ABVC-BioPharma-Reports-Annual-2023-Financials-and-Provides-Fiscal-Year-2024-First-Quarter-Business-Update.htmlFREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ABVC_OUT_13 [2025-04-01 09:56:13 -0400] 1126 Bytes | 299 tokens | Cum: 2789 tkns (34.86% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-01-06 8-K Item 1.01 Entry into a Material Definitive Agrmt.

As previously reported, over the past year, ABVC BioPharma, Inc. (the Company ) has entered into three securities purchase agreements with Lind Global Fund II, LP ( Lind ), pursuant to which the Company has issued to Lind: (...

S2 - 2025-01-06 8-K Item 1.01 Entry into a Material Definitive Agrmt.

As previously reported, over the past year, ABVC BioPharma, Inc. (the Company ) has entered into three securities purchase agreements with Lind Global Fund II, LP ( Lind ), pursuant to which the Company has issued to Lind: (...

S3 - 2024-11-14 8-K Item 2.02 Results of Oper and Fin Cond.

On November 14, 2024, ABVC BioPharma, Inc. (the Company ) issued a press release announcing its financial results for the third quarter ended September 30, 2024, which were disclosed in the Quarterly Report on Form 10-Q f...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ABVC_OUT_15 [2025-04-01 09:56:18 -0400] 1098 Bytes | 276 tokens | Cum: 3067 tkns (38.34% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item 1.01 Entry into a Material Definitive Agreement.

As previously reported, over the past year, ABVC BioPharma, Inc. (the Company ) has entered into three securities purchase agreements with Lind Global Fund II, LP ( Lind ), pursuant to which the Company has issued to Lind: (i) 3,527,778 shares of the Companys common stock, par value $0.001 per share (the Common Stock ) underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of February 23, 2023 between the Company and Lind (the Lind Transaction ); (ii) 5,291,667 shares of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 342,857 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of November 17, 2023 between the Company and Lind (the 2 nd Lind Transa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ABVC_OUT_17 [2025-04-01 09:56:24 -0400] 1098 Bytes | 276 tokens | Cum: 3423 tkns (42.79% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): ction ); (iv) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 2 nd Lind Transaction; (v) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the 3 rd Lind Transaction , together with the Lind Transaction and 2 nd Lind Transaction, the Initial Lind Transactions ) and (vi) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3 rd Lind Transaction. On May 22, 2024, the Company and Lind entered into a letter agreement (the May Letter Agreement ), pursuant to which Lind exercised, for cash, 1,000,000 of the Existing Warrants to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Lind also received a new warrant to purchase 1,000,000 shares

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ABVC_OUT_19 [2025-04-01 09:56:35 -0400] 4198 Bytes | 1196 tokens | Cum: 4735 tkns (59.19% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 263,699 | Perf Month: 84.00% | Option/Short: No / Yes | Sales Y/Y TTM: -31.04% |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 527.16K | Perf Quarter: 118.51% | Short Float: 2.86% | ROE: -90.91% |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 6.73 | Index: - | Short Ratio: 0.61 | ROI: -96.97% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 87.73 | Market Cap: 16.47M | Short Interest: 0.32M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.08 | Shs Outstand: 12.71M | Beta: 0.33 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: 73.40% | Shs Float: 11.24M | Sales Q/Q: 2350.74% | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: 102.44% | Inst Own: 3.15% | Sales past 5Y: 7.69% | Earnings: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: 98.47% | Insider Own: 13.39% | Employees: - | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: 84.59% | Insider Trans: 0.00% | Debt/Eq: 0.33 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 389276, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -134272, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.29
Average Volume: 186725.82
30-Day High: 1.29
30-Day Low: 0.6324

[Detailed Financials: Q3 2024]
- Total Assets: $14,462,845.0
- Total Liabilities: $6,483,523.0
- Total Equity: $7,979,322.0
- Current Assets: $2,148,327.0
- Current Liabilities: $6,315,642.0

[Income Statement: Q3 2024]
- Revenue: $389,276.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.02

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-773

[Detailed Financials: Q2 2024]
- Total Assets: $14,633,699.0
- Total Liabilities: $6,805,409.0
- Total Equity: $7,828,290.0
- Current Assets: $2,189,567.0
- Current Liabilities: $6,548,927.0

[Income Statement: Q2 2024]
- Revenue: $117,142.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.09

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-229,324
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ABVC_OUT_21 [2025-04-01 09:56:37 -0400] 676 Bytes | 167 tokens | Cum: 5132 tkns (64.15% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ABVC_IN_23 [2025-04-01 09:56:38 -0400] 126 Bytes | 29 tokens | Cum: 5189 tkns (64.86% of 8k)
==========================================================================

====================================
[2025-04-01 09:56:38] # Analysis Completed
Elapsed Time: 41.93 seconds